Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
225.43
-6.56 (-2.83%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
38
39
Next >
Biogen Has An $8 Billion Alzheimer's Opportunity — Will It Materialize?
March 03, 2022
A few key things have to go right for Biogen to snag a definitive win in Alzheimer's.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022
March 03, 2022
Upgrades For Douglas Emmett Inc (NYSE:DEI), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Douglas Emmett had an EPS of $0.48,...
Via
Benzinga
10 Biggest Price Target Changes For Thursday
March 03, 2022
Piper Sandler cut the price target on Bright Health Group, Inc. (NYSE: BHG) from $10 to $5. Bright Health shares rose 3.2% to $2.59 in pre-market trading.
Via
Benzinga
What 24 Analyst Ratings Have To Say About Biogen
February 04, 2022
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:
Via
Benzinga
Analyst Ratings For Biogen
February 04, 2022
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:
Via
Benzinga
Biogen: Q4 Earnings Insights
February 03, 2022
Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
How Many Stocks Are Down From Their Pre-COVID Levels?
February 21, 2022
On February 19th, 2020, the S&P 500 made its last closing high prior to all hell breaking loose for the next month.
Via
Talk Markets
Why A Biogen-Sage Drug Flopped — And Could Still Be Approved
February 16, 2022
The companies tested a combination of zuranolone and depression drugs.
Via
Investor's Business Daily
Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study
February 16, 2022
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing...
Via
Benzinga
US Senate Narrowly Votes In Favor Of Biden's Nominee Robert Califf To Lead FDA For Second Time
February 16, 2022
By a narrow vote of 50-46, the Senate has confirmed Robert Califf to run the FDA. Califf, who previously served as the FDA commissioner from February 2016 to January...
Via
Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...
Via
Benzinga
Biogen's Alzheimer's Struggles Continue; 'Minimal' Sales Expected This Year
February 03, 2022
Biogen's new Alzheimer's drug generated $1 million in fourth-quarter sales.
Via
Investor's Business Daily
Recap: Biogen Q4 Earnings
February 03, 2022
Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
February 17, 2022
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company...
Via
Benzinga
Revisiting the Biggest Winners and Losers Since the COVID Crash Low
February 16, 2022
A look at how the average stock that’s currently in the S&P 1500 has done since the Covid crash low by sector.
Via
Talk Markets
Large Cap Biopharma- Well Positioned For Choppy Markets
February 14, 2022
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets.
Via
Talk Markets
Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
February 08, 2022
Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have
Via
Benzinga
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
February 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For February 3, 2022
February 03, 2022
Companies Reporting Before The Bell • Tuesday Morning (NASDAQ:TUEM) is likely to report earnings for its second quarter.
Via
Benzinga
10 Biggest Price Target Changes For Monday
February 07, 2022
BMO Capital cut the price target for Match Group, Inc. (NASDAQ: MTCH) from $150 to $130. Match Group shares fell 1.4% to trade at $114.33 on Monday.
Via
Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
February 06, 2022
Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came...
Via
Talk Markets
Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes
February 04, 2022
The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm...
Via
Benzinga
Stock Market Rally Volatile; Google, Facebook, Amazon, Snap Are Earnings Movers: Weekly Review
February 04, 2022
The major indexes slashed weekly gains after Monday's follow-through day.
Via
Investor's Business Daily
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 4, 2022
February 04, 2022
Upgrades CBRE upgraded the previous rating for Penn National Gaming Inc (NASDAQ:PENN) from Hold to Buy. For the fourth quarter, Penn National Gaming had an EPS of $0.26,...
Via
Benzinga
10 Biggest Price Target Changes For Friday
February 04, 2022
JP Morgan boosted the price target for Amazon.com, Inc. (NASDAQ: AMZN) from $4,350 to $4,500. Amazon shares jumped 11% to $3,081.07 in pre-market trading.
Via
Benzinga
Facebook FB plunges but Amazon AMZN surges: Earnings and Your Updated Price Levels
February 03, 2022
It seems like yesterday we were discussing the surge in Alphabet shares, and today we're focusing on big moves - currently in opposite directions - of Facebook and Amazon, all major market cap...
Via
Talk Markets
Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus
February 03, 2022
Biogen Inc (NASDAQ: BIIB) posted Q4 sales of 2.73 billion, beating the consensus of $
Via
Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
February 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
February 03, 2022
On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And Highs: Meta Platforms (NASDAQ:FB) was the biggest company on...
Via
Benzinga
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.